BRAF and NRAS mutations in melanoma: potential relationships to clinical response to HSP90 inhibitors

MLA

Udai Banerji, et al. “BRAF and NRAS Mutations in Melanoma: Potential Relationships to Clinical Response to HSP90 Inhibitors.” Molecular Cancer Therapeutics, vol. 7, no. 4, Apr. 2008. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....f72606924884a1996ef4d2c0434a87c3&authtype=sso&custid=ns315887.

APA

Udai Banerji, Paul Workman, Annette Affolter, Ian Judson, & Richard Marais. (2008). BRAF and NRAS mutations in melanoma: potential relationships to clinical response to HSP90 inhibitors. Molecular Cancer Therapeutics, 7(4).

Chicago

Udai Banerji, Paul Workman, Annette Affolter, Ian Judson, and Richard Marais. 2008. “BRAF and NRAS Mutations in Melanoma: Potential Relationships to Clinical Response to HSP90 Inhibitors.” Molecular Cancer Therapeutics 7 (4). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....f72606924884a1996ef4d2c0434a87c3&authtype=sso&custid=ns315887.